<DOC>
	<DOCNO>NCT00111709</DOCNO>
	<brief_summary>The purpose study test effectiveness market drug treatment menstrual migraine attack .</brief_summary>
	<brief_title>Study Test Marketed Drug Treatment Menstrual Migraine ( 0462-071 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Female patient least 18 year old Patient menses approximately monthly Patient least 5 month history migraine least 6 month history menstrual migraine Pregnant and/or nursing Cardiovascular disease Uncontrolled hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>